Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum toxin intradermal injection for rosacea-related erythema and flushing
ChiCTR2100052705Phase 4Completed
- Sponsor
- Chengdu Second People's Hospital
- Start
- Dec 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of neuronox in rosacea (2 arms), sponsored by Chengdu Second People's Hospital. Primary endpoint: Global Flushing Symptom Score. Started Dec 2020; status: completed.
02
Drugs
neuronox
03
Conditions
rosacea
Beyond the preview
Go deeper on ChiCTR2100052705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052705.